Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Reactive antibodies against bacillus Calmette-Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder.

Ardelt PU, Kneitz B, Adam P, Reiss C, Kocot A, Fensterle J, Chen L, Pasqualini R, Arap W, Gerharz EW, Riedmiller H.

Cancer. 2010 Feb 1;116(3):600-9. doi: 10.1002/cncr.24770.

2.

Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.

Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M, Pirson M, Jurion F, Palfliet K, Denis O, Mascart F, Simon J, Schulman CC, Van Vooren JP.

Clin Exp Immunol. 1997 Jul;109(1):157-65.

3.

Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy.

Zlotta AR, Drowart A, Van Vooren JP, Shekarsarai H, De Cock M, Pirson M, Palfliet K, Jurion F, Simon J, Schulman CC, Huygen K.

J Urol. 1998 Jun;159(6):1885-91.

PMID:
9598481
4.

High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).

Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):223-7.

PMID:
16767936
5.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.

J Urol. 2000 Apr;163(4):1124-9.

PMID:
10737480
6.
7.

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.

Martínez-Piñeiro JA, Jiménez León J, Martínez-Piñeiro L Jr, Fiter L, Mosteiro JA, Navarro J, García Matres MJ, Cárcamo P.

J Urol. 1990 Mar;143(3):502-6.

PMID:
2106041
9.

Long term protection in bladder cancer following intralesional immunotherapy.

Reichert DF, Lamm DL.

J Urol. 1984 Sep;132(3):570-3.

PMID:
6381762
10.

Immunotherapeutic strategies for high-risk bladder cancer.

Sharma P, Old LJ, Allison JP.

Semin Oncol. 2007 Apr;34(2):165-72. Review.

PMID:
17382800
12.

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?

Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.

BJU Int. 2009 Jul;104(2):179-83. doi: 10.1111/j.1464-410X.2008.08299.x.

13.

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.

Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM.

J Urol. 1985 Jul;134(1):48-53.

PMID:
3892051
14.
15.

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.

Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.

J Urol. 2000 Dec;164(6):2129-33.

PMID:
11061941
16.

Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.

Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, Chopin DK.

Eur Urol. 2003 Apr;43(4):351-60; discussion 360-1. Review.

PMID:
12667715
17.

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.

Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J.

J Urol. 2001 May;165(5):1488-91.

PMID:
11342902
18.

BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.

Bassi P.

Surg Oncol. 2002 Jun;11(1-2):77-83. Review.

PMID:
12031870
19.

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al.

N Engl J Med. 1991 Oct 24;325(17):1205-9.

20.

Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer.

Cheng C, Consigliere D, Foo KT, Tan EC, Tung KH, Tock EP.

Ann Acad Med Singapore. 1995 Jul;24(4):562-5.

PMID:
8849189

Supplemental Content

Support Center